Sentynl Therapeutics And Mereo Biopharma Announce Option And License Agreement For Alvelestat In Alpha-1 Antitrypsin Deficiency-Associated Lung Disease
MREO•Option and license agreement for alvelestat
Aug. 11 (Reuters) - Mereo Biopharma Group PLC MAH0y.F:
- Sentynl Therapeutics and Mereo Biopharma announce option and license agreement for alvelestat in alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD)
- Sentynl Therapeutics - Sentynl and Mereo enter option and license agreement for alvelestat in AATD-LD
- Sentynl Therapeutics - On option exercise, Sentynl to commercialize alvelestat in U.S.; Mereo retains rest of world rights
- Sentynl Therapeutics - Mereo to receive up to $40 million in payments and double-digit tiered royalties on U.S. sales
Source text: ID:nPnbBXbDKa
Further company coverage: [MAH0y.F]
